Opdivo (nivolumab) represents a fundamental shift in how doctors treat melanoma and other cancers, moving away from traditional chemotherapy toward therapies that harness your body's own immune system. This immunotherapy drug works by removing the "camouflage cloak" that allows cancer cells to evade detection, enabling your immune cells to recognize and attack tumors more effectively. For patients with advanced melanoma and other difficult-to-treat cancers, this approach has opened new treatment possibilities.

What Makes Checkpoint Inhibitors Different From Traditional Cancer Treatment?

For decades, cancer treatment relied on chemotherapy drugs that attacked all rapidly dividing cells in the body, causing significant side effects and damage to healthy tissue. Opdivo and similar checkpoint inhibitors represent what oncologists call "molecular precision," explained Julie Gralow, MD, chief medical officer and executive vice president of the American Society of Clinical Oncology (ASCO).

"Instead of just chemotherapy that targets all rapidly dividing cells, we have become much more targeted and much more elegant," Gralow stated.

Julie Gralow, MD, Chief Medical Officer and Executive Vice President, American Society of Clinical Oncology

Opdivo works by blocking a protein called PD-1 on T-cells, which are immune cells responsible for fighting cancer. Cancer cells produce a protein called PD-L1 that binds to PD-1, essentially telling your immune system to stand down. By blocking this interaction, Opdivo "releases the brake" on your immune system, allowing T-cells to recognize and destroy cancer cells.

Which Cancers Can Opdivo Treat?

Since its development, Opdivo has been approved to treat a wide range of cancers beyond melanoma. The drug's versatility reflects how broadly applicable checkpoint inhibition has become in modern oncology.

• Melanoma: Advanced melanoma in adults and certain types in children aged 12 and older
• Lung Cancer: Non-small cell lung cancer (NSCLC), including cases that can be surgically removed and advanced cases that have spread
• Kidney Cancer: Renal cell carcinoma (RCC) when the cancer has spread to other parts of the body
• Bladder Cancer: Urothelial carcinoma that has advanced or spread
• Lymphoma: Classical Hodgkin lymphoma, a cancer of the lymphatic system
• Head and Neck Cancer: Squamous cell carcinoma affecting the head and neck region
• Gastrointestinal Cancers: Hepatocellular carcinoma (liver), esophageal cancer, gastric cancer, and colorectal cancer in specific cases
• Genetic Markers: Cancers with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) features

The decision to use Opdivo depends on your specific cancer type, stage, and overall health. Your oncologist may recommend it alone or in combination with other medications, such as Yervoy (ipilimumab), another checkpoint inhibitor that works through a different mechanism.

How Is Opdivo Administered, and What Should You Expect?

Unlike oral chemotherapy pills, Opdivo is administered as an intravenous (IV) infusion directly into your vein, typically over about 30 minutes. The dosage and frequency are highly personalized based on your cancer type, stage, body weight, and overall health status. Most adults receive infusions once every 2, 3, 4, or 6 weeks, while children may receive treatment once every 2, 3, or 4 weeks.

Because Opdivo is a biologic drug derived from living organisms, it requires careful medical supervision. Your healthcare team will monitor you closely throughout treatment to assess how well the drug is working and to manage any side effects that develop.

What Side Effects Should You Watch For?

While many patients tolerate Opdivo well, the drug can cause both mild and serious side effects. The most common mild side effects include fatigue, rash, itching, diarrhea, nausea, muscle or joint pain, shortness of breath, fever, and cough. These are often manageable with supportive care.

More concerning are immune-related side effects, which occur when the activated immune system mistakenly attacks healthy tissues and organs. These can affect multiple body systems and require immediate medical attention.

• Lung Inflammation: Pneumonitis can cause shortness of breath, cough, and chest pain
• Intestinal Inflammation: Colitis leads to severe diarrhea, blood in the stool, and abdominal pain
• Liver Inflammation: Hepatitis causes jaundice (yellowing of skin and eyes), dark urine, and abdominal pain
• Hormone Gland Problems: Inflammation of the pituitary, thyroid, or adrenal glands can cause fatigue, weight changes, headaches, and mood changes
• Kidney Issues: Changes in urination patterns may indicate kidney problems
• Nervous System Effects: Neurological complications can include numbness, tingling, or weakness
• Severe Skin Reactions: Serious rashes or blistering may develop
• Heart Inflammation: Myocarditis, inflammation of the heart muscle, is a rare but serious complication

Contact your doctor immediately if you experience any new or worsening symptoms, especially those listed above. If you believe you are experiencing a medical emergency, call 911 or your local emergency services right away.

How to Manage Your Treatment and Minimize Risks

• Open Communication: Report all symptoms to your doctor honestly and promptly, even if they seem minor or unrelated to your cancer treatment
• Attend All Appointments: Keep all scheduled infusions and follow-up visits to ensure consistent treatment and close monitoring
• Use Supportive Care: Your doctor may prescribe medications to manage side effects like nausea, itching, or diarrhea, which can significantly improve your quality of life
• Maintain Healthy Habits: Follow your doctor's guidance on nutrition and hydration, as these support your body's ability to tolerate treatment
• Inform Your Team of All Medications: Tell your oncologist about any other drugs, supplements, or herbal products you are taking, though Opdivo has no known interactions with other medications

The evolution of cancer treatment over the past 40 years has been dramatic. Opdivo and other checkpoint inhibitors represent a major milestone in this journey, moving oncology from "blunt instrument" chemotherapy to precision therapies that work with your body's natural defenses. For patients with melanoma and other cancers, this shift offers hope for better outcomes and improved quality of life during treatment.

If you have been diagnosed with melanoma or another cancer that might benefit from checkpoint inhibitor therapy, discuss Opdivo and other immunotherapy options with your oncologist. Your medical team can help determine whether this treatment is right for you and what to expect during your care journey.